GWAAIS 2022 Academic Conference Series - September 21

Bethesda, MD US
September 21, 2022

Food Allergy: Updates on Diagnosis and Immunotherapy. This lecture will examine the most updaed laboratory technologies and the use of immunomodulating therapies to include sublingual and oral immunotherapies.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Greater Washington Allergy, Asthma & Immunology Society (GWAAIS). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists, fellows- in- training in allergy and immunology, primary care physicians, and allied health care providers in the field of allergy and immunology.

Learning Objectives

Upon completion of this activity, participants should be able to:
Appropriately diagnose food allergies using the most updated laboratory technologies. Actively manage and treat food allergies using immunomodulating therapies to include sublingual and oral immunotherapies.

 

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
Course opens: 
09/21/2022
Course expires: 
09/20/2024
Event starts: 
09/21/2022 - 7:15pm CDT
Event ends: 
09/21/2022 - 8:30pm CDT
Rating: 
0

Greater Washington Allergy, Asthma and Immunology Society
Third Academic Conference Series 2022

September 21, 2022
Bethesda Country Club, 7601 Bradley Blvd., Bethesda, Maryland 20817, (301) 365-1700
AGENDA
6:00pm-7:00pm             Exhibits | Registration | Reception

7:00pm-7:15pm             Welcome & Introduction
Theodore T. Kim, MD – President, GWAAIS

7:15pm-8:15pm             “Food Allergy: Updates on Diagnosis and Immunotherapy”
Speaker: Dr. Robert Wood, Professor, Pediatrics Johns Hopkins University, Baltimore, Maryland

8:15pm-8:30pm             Questions and Answer Session.

8:30pm                  Adjourn.


Target Audience: Practicing allergists, fellows- in- training in allergy and immunology, primary 
care physicians, and allied health care providers in the field of allergy and immunology.

Learning Objectives: Upon completion of this activity, participants should be able to:
Appropriately diagnose food allergies using the most updated laboratory technologies. Actively 
manage and treat food allergies using immunomodulating therapies to include sublingual and oral 
immunotherapies.

Accreditation: This activity has been planned and implemented in accordance with the accreditation 
requirements and policies of the Accreditation Council for Continuing Medical Education through the 
joint providership of the American College of Allergy, Asthma and Immunology (ACAAI) and the 
Greater Washington Allergy, Asthma and Immunology Society (GWAAIS). The American College of 
Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing 
Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation
The American College of Allergy, Asthma and Immunology (ACAAI) designates this live activity for a 
maximum of
1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the 
extent of their participation in the activity.

In compliance with the Americans with Disabilities Act, GWAAIS requests that any participant in 
need of
accommodation contact Kay Kim, email: GWAAISDMV@gmail.com

 

Bethesda Country Club
7601 Bradley Blvd.
Bethesda, MD 20817
United States
+1 (301) 365-1700

All identified conflicts of interest have been mitigated.

The individuals listed below disclose the following financial relationships:
 
Robert Wood, MD, Speaker
Research Support from:
•    NIAID
•    CDC
•    FARE
•    Aimmune
•    ALK
•    Astellas
•    DBV
•    Genentech
•    HAL-Allergy
•    Novartis
•    Regeneron
•    Sanofi
•    Siolta Therapeutics

Theodore Kim, MD, planner
No relevant financial relationships to disclose

 Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma and Immunology (ACAAI) and the Greater Washington Allergy, Asthma and Immunology Society (GWAAIS).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation

The American College of Allergy, Asthma and Immunology (ACAAI) designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 In compliance with the Americans with Disabilities Act, GWAAIS requests that any participant in need of accommodation contact Kay Kim, email: GWAAISDMV@gmail.com

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Attendance
Please login or create an account to take this course.